Ask AI
ET Case Challenge

CME

Interactive Case Challenge: Diagnosing and Managing a Patient With Essential Thrombocythemia

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: April 06, 2026

Expiration: October 05, 2026

Activity

Progress
1 2
Course Completed

Case Follow-Up
The patient began treatment with aspirin plus hydroxyurea. Although the hydroxyurea dose is titrated, it is difficult to achieve normal platelet counts. A CBC demonstrates hemoglobin 10.9 g/dL, WBC 3.4 x 109/L, platelets 617 x 109/L, and neutrophils 1.64 x 109/L.

The patient arrives to discuss the next steps in her treatment. She is interested in considering a clinical trial if this fits with her overall goals of therapy.

In discussing clinical trial options with the patient, which of the following would you tell her is an LSD1 inhibitor that has shown activity in previously treated ET and is currently in phase III assessment?